Cello Health (CLL)

Sector:

Health Care

Index:

FTSE AIM All-Share

 161.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 163.50p
  • 52 Week Low: 101.00p
  • Currency: UK Pounds
  • Shares Issued: 106.69m
  • Volume: 30,263
  • Market Cap: £171.77m
  • RiskGrade: 352

Cello warns on profits after retail setbacks

Date: Wednesday 06 Jul 2011

LONDON (ShareCast) - Advertising and marketing group Cello expects profits for the full year to fall short of expectations after losing a retail research contract earlier this month and seeing one of its retail clients entering administration.

The company expects to incur a full year exceptional charge of about £500,000. While pre-tax profits for the full year will be “slightly lower than management's previous expectations”, Cello says that it traded in line with expectations in the six months to 30 June.

Cello’s list of clients includes big names such as the drug companies AstraZeneca and Pfizer and the brewer Carlsberg.

“Cello is fast developing into a global research and consulting business, with a distinctive focus on the pharmaceutical sector, along with other international, high margin client sectors,” said chief executive Mark Scott.

“Combined with a focused innovation drive, particularly behind social media based research, we are confident that this strategy will deliver strong shareholder value."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Cello Health Market Data

Currency UK Pounds
Share Price 161.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 163.50p
52 Week Low 101.00p
Volume 30,263
Shares Issued 106.69m
Market Cap £171.77m
RiskGrade 352

Cello Health Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
86.02% below the market average86.02% below the market average86.02% below the market average86.02% below the market average86.02% below the market average
Sector averageSector averageSector averageSector averageSector average
Price Trend
81.60% above the market average81.60% above the market average81.60% above the market average81.60% above the market average81.60% above the market average
53.85% above the sector average53.85% above the sector average53.85% above the sector average53.85% above the sector average53.85% above the sector average
Income
76.62% below the market average76.62% below the market average76.62% below the market average76.62% below the market average76.62% below the market average
38.46% above the sector average38.46% above the sector average38.46% above the sector average38.46% above the sector average38.46% above the sector average
Growth
30.41% below the market average30.41% below the market average30.41% below the market average30.41% below the market average30.41% below the market average
47.06% below the sector average47.06% below the sector average47.06% below the sector average47.06% below the sector average47.06% below the sector average

What The Brokers Say

Strong Buy 0
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 1
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Cello Health Dividends

  Latest Previous
  2nd Interim Interim
Ex-Div 23-Apr-20 03-Oct-19
Paid 22-May-20 01-Nov-19
Amount 1.00p 1.15p

Trades for 07-Aug-2020

Time Volume / Share Price
16:30 618 @ 160.00p
16:03 11,000 @ 160.00p
16:01 8,003 @ 160.00p
15:21 310 @ 160.00p
15:19 8,000 @ 160.00p

Cello Health Key Personnel

CEO Mark Scott

Top of Page